Paper Details
- Home
- Paper Details
[Effects of epsilon-aminocaproic acid, amben and kontrikal on fibrinolysis due to tissue-type plasminogen activator from the pig heart].
Author: AlievaN I, AndreenkoG V, ShimonaevaE E
Original Abstract of the Article :
Simultaneous intravenous administration to rats of epsilon-aminocaproic acid and high doses of plasminogen tissue activator from the pig heart was shown to prevent fibrinolysis changes induced by the tissue activator. Amben completely suppressed the action of the tissue activator at the blood concen...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元:
https://pubmed.ncbi.nlm.nih.gov/2428660
データ提供:米国国立医学図書館(NLM)
Controlling Fibrinolysis: A Comparative Study of Anti-Fibrinolytic Agents
Fibrinolysis is a crucial physiological process involved in dissolving blood clots. This study investigates the effects of different anti-fibrinolytic agents, including epsilon-aminocaproic acid, amben, and kontrikal, on fibrinolysis induced by tissue-type plasminogen activator (tPA). The researchers aimed to compare the efficacy of these agents in controlling fibrinolysis, providing valuable insights into their therapeutic potential.
Amben: A Potent Anti-Fibrinolytic Agent
The study revealed that amben effectively suppressed the activity of tPA, demonstrating a significantly greater effect compared to epsilon-aminocaproic acid and kontrikal. This finding highlights the potential of amben as a potent anti-fibrinolytic agent, particularly in situations where rapid and effective control of fibrinolysis is crucial.
Harnessing Anti-Fibrinolytic Agents for Clinical Applications
The study's findings have implications for the clinical management of conditions involving excessive fibrinolysis, such as bleeding disorders or post-surgical bleeding. By understanding the comparative efficacy of different anti-fibrinolytic agents, healthcare professionals can select the most appropriate therapy for each patient, optimizing treatment outcomes and minimizing the risk of complications.
Dr.Camel's Conclusion
This study provides valuable insights into the comparative efficacy of different anti-fibrinolytic agents, highlighting the potential of amben as a potent inhibitor of fibrinolysis. The findings have implications for the clinical management of bleeding disorders and other conditions requiring rapid control of fibrinolysis, offering healthcare professionals a more comprehensive understanding of therapeutic options available to optimize patient outcomes.
Date :
- Date Completed 1986-10-31
- Date Revised 2013-11-21
Related Literature
Russian
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.